Fate Therapeutics (FATE) Prices 4.421M Share Common Offering at $85/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Pre-Open Stock Movers 01/05: (BPFH) (MRKR) (FUBO) Higher; (EGHT) (FATE) (VRAY) Lower (more...)
January 5, 2021 9:30 AM ESTPre-Open Stock Movers:
Boston Private Financial Holdings, Inc. (NASDAQ: BPFH) 28.3% HIGHER; SVB Financial Group (NASDAQ: SIVB), the parent of Silicon Valley Bank, the bank of the world's most innovative... More
After-Hours Stock Movers 01/04: (IO) (LIFE) (AIH) Higher; (FATE) (GBIO) Lower (more...)
January 4, 2021 6:02 PM ESTAfter-Hours Stock Movers:
ION Geophysical Corporation (NYSE: IO) 17.8% HIGHER; announced the first proprietary commercial deployment of the Companys Gemini extended frequency source technology for a Super Major. Following the technologys commercialization in September, energy companies have specified Gemini in a number of proprietary tenders, the first of which... More
Fate Therapeutics (FATE) Announces Proposed $350M Share Common Offering
January 4, 2021 4:02 PM ESTFate Therapeutics Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering of $350 million of shares of common stock. Fate Therapeutics intends to use the net proceeds from the offering to fund clinical... More
